ResMed (RMD) Q3 2025: Gross Margin Rises 140bps as Tariff Exemption Secures U.S. Profitability
ResMed’s Q3 saw margin expansion and robust cash flow, powered by operational discipline, automation, and tariff relief. Strategic investments in U.S. manufacturing, digital diagnostics, and demand generation signal a multi-year push to expand the sleep health funnel and outpace market growth. With supply chain resilience and a clear capital allocation plan, ResMed is positioning for sustainable earnings leverage into FY26.
Summary
- Tariff Exemption Locks in U.S. Margin: ResMed’s long-standing U.S. tariff relief was reaffirmed, insulating profitability from global trade shocks.
- Automation and Mix Drive Margin Expansion: Manufacturing and logistics efficiencies, plus product mix, pushed gross margin near 60%.
- Scaling Digital Diagnostics and Demand Gen: Investments in Night Owl, VPAP-TX, and targeted marketing are designed to unlock new patient flows and accelerate growth.
Performance Analysis
ResMed delivered 8% top-line growth in Q3, with device and mask sales both contributing. The U.S., Canada, and Latin America posted 9% growth, while Europe, Asia, and other regions added 8% in constant currency. Device sales rose 7% globally, but mask and other sales outpaced at 12%, highlighting the ongoing strength of resupply and adherence programs. Residential care software advanced 10%, powered by the Medifox Darn vertical, demonstrating the growing role of digital solutions in the business mix.
Gross margin expanded by 140 basis points to 59.9%, driven by manufacturing and logistics efficiencies, a favorable shift toward higher-margin masks, and ongoing component cost improvements. SG&A and R&D investments grew in line with revenue, reflecting increased marketing behind the refreshed global brand and continued commitment to innovation. Operating profit rose 13%, and free cash flow was robust, with $472 million generated even after adjusting for a tax refund. ResMed’s net cash position and $1.5 billion in available credit provide ample liquidity for both organic and inorganic growth.
- U.S. Mask Sales Outperformance: Masks grew 13% in the Americas, outstripping device growth and reflecting strong adherence and resupply momentum.
- Gross Margin Upside from Scale and Automation: Efficiencies in manufacturing and logistics, plus improved product mix, were major contributors to margin gains.
- Cash Flow Strength Underpins Buybacks: High free cash flow enabled an increased share buyback pace to $100 million per quarter, supporting shareholder returns.
Overall, ResMed’s performance reflects a blend of disciplined execution, margin expansion, and strategic investment, with the business model showing resilience against macro and regulatory headwinds.
Executive Commentary
"We delivered solid revenue growth, gross margin expansion both sequentially and year on year, very strong free cash flow generation and maintained our disciplined approach to investments in both research and development and SG&A. This performance reflects broad-based momentum and disciplined execution to capture growing demand for our products."
Mick Farrell, Chairman and CEO
"Gross margin increased by 140 basis points to 59.9% in the March quarter. The year-over-year increase was primarily driven by manufacturing and logistics efficiencies, as well as favorable shifts in product mix, partially offset by unfavorable foreign currency movements. We continue to make good progress on our gross margin expansion initiatives and we are focused on making sustained long-term gross margin improvements."
Brett, Finance Executive
Strategic Positioning
1. Tariff Exemption Secures U.S. Profitability
ResMed’s reaffirmed U.S. tariff exemption for its Australian and Singapore-manufactured devices neutralizes a major risk impacting competitors. This advantage ensures cost stability and margin protection in the company’s largest market, while peers importing from China or other high-tariff countries may face significant cost headwinds.
2. U.S. Manufacturing Expansion and Automation
The new Calabasas, California facility will double U.S. manufacturing footprint, increase core motor and mask capacity, and leverage advanced automation. This move not only enhances supply chain resilience but also brings production closer to demand, reducing logistics costs and supporting future growth in the U.S. market.
3. Digital Health Ecosystem and Diagnostic Funnel Expansion
With the full U.S. commercial launch of Night Owl, a home sleep apnea test, and the new VPAP-TX platform for sleep labs, ResMed is expanding the diagnostic funnel to address persistent sleep lab backlogs. Integration with AirView and Somnaware creates an end-to-end, cloud-connected pathway from diagnosis to therapy adherence, supporting both volume and retention.
4. Demand Generation and Brand ROI Discipline
ResMed is investing in targeted CME education and streaming ads to drive physician and consumer awareness, with a strict focus on measurable ROI. Early results show increased prescriptions and patient flow, with the company scaling these programs city by city to maximize conversion efficiency.
5. Capital Allocation and Shareholder Returns
With a net cash balance and strong cash flow, ResMed is increasing its share buyback pace to $100 million per quarter and maintaining its dividend, while continuing to reinvest in R&D and actively pursue tuck-in acquisitions aligned with its 2030 strategy.
Key Considerations
ResMed’s Q3 reflects a company balancing operational discipline, innovation, and strategic investment to drive sustainable growth and margin leverage. Several considerations shape the investment case:
Key Considerations:
- Gross Margin Pipeline: Ongoing initiatives in manufacturing, logistics, and procurement are expected to drive further margin expansion toward and potentially above 60%.
- Diagnostic Capacity Bottleneck: Sleep lab backlogs remain a constraint, but Night Owl and digital integration aim to accelerate patient onboarding and therapy starts.
- GLP-1 and Wearables Demand Tailwind: The rise of GLP-1 medications and consumer wearables is expanding the addressable market for sleep diagnostics and therapy, with ResMed building infrastructure for increased patient flow.
- Capital Allocation Flexibility: Strong liquidity enables a balanced approach to buybacks, dividends, R&D, and M&A, with management emphasizing ROI and strategic fit for any acquisitions.
- Tariff and Regulatory Shield: U.S. tariff exemption uniquely protects ResMed’s cost structure, providing a competitive moat in the current trade environment.
Risks
Key risks include persistent sleep lab backlogs limiting device volume growth, potential delays or underperformance in digital diagnostic adoption, and competitive responses to ResMed’s tariff advantage. Foreign exchange volatility and macroeconomic pressures could also affect results, though the business is well shielded from acute regulatory or supply chain shocks. Execution on demand generation and adherence programs will be critical to sustaining outperformance.
Forward Outlook
For Q4 2025, ResMed guided to:
- Gross margin broadly consistent with Q3, with upside bias if FX remains favorable
- SG&A as a percentage of revenue in the 18% to 20% range
- R&D as a percentage of revenue in the 6% to 7% range
For full-year 2025, management maintained guidance:
- Effective tax rate of 19% to 21%
Management highlighted several factors that will drive results:
- Continued margin expansion initiatives and automation
- Scaling of Night Owl and digital diagnostics to unlock new patient flow
Takeaways
ResMed’s Q3 underscores structural margin gains and a unique regulatory shield in the U.S. market, while investments in automation and digital health position the company for sustained above-market growth.
- Margin Expansion Is Durable: Multiple efficiency levers and product mix shifts are supporting sustainable gross margin improvement, with a credible path above 60%.
- Tariff Relief Is a Competitive Moat: ResMed’s reaffirmed exemption protects earnings and cash flow, while competitors face new cost headwinds.
- Watch Digital Funnel Metrics: The pace at which Night Owl, VPAP-TX, and demand generation initiatives translate into new patient starts and adherence will be the key forward catalyst.
Conclusion
ResMed’s Q3 combined operational discipline, automation, and a unique regulatory position to deliver strong margin and cash flow gains. With digital health investments and a robust capital allocation plan, the company is building the foundation for multi-year outperformance and resilience in a dynamic global healthcare landscape.
Industry Read-Through
ResMed’s tariff exemption and automation investments highlight the strategic importance of manufacturing footprint and regulatory navigation in medtech. Competitors importing from China or other high-tariff regions face rising cost pressure, underscoring the value of diversified supply chains and local production. The shift toward digital diagnostics and demand generation is accelerating across the sector, with patient funnel expansion and adherence now critical growth drivers. Industry peers should closely watch the impact of GLP-1 adoption and consumer wearables on sleep and respiratory health market expansion, as well as the ROI discipline in digital health investments.